January 22, 2018 / 1:32 PM / a year ago

BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma

Jan 22 (Reuters) - Takeda Pharmaceutical Co Ltd:

* EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS

* TAKEDA PHARMACEUTICAL- PHASE 3 ALCANZA STUDY DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RATE OF OBJECTIVE RESPONSE LASTING ATLEAST 4 MONTHS

* TAKEDA PHARMACEUTICAL CO LTD - EUROPEAN COMMISSION EXTENDED CURRENT CONDITIONAL MARKETING AUTHORIZATION OF ADCETRIS

* TAKEDA PHARMACEUTICAL- EC APPROVED ADCETRIS FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below